| Deana Mamari, DEANA | |
|
18200 Lorain Ave, Cleveland, OH 44111-5605 | |
| (216) 316-2697 | |
| Not Available |
| Full Name | Deana Mamari |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 11 Years |
| Location | 18200 Lorain Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831533082 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Hospital | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
An Australian-Dutch trial led by Perth GenesisCare cardiologists, Professor Peter Thompson and Dr Mark Nidorf, in collaboration with the Dutch Network for Cardiovascular Research (WCN) in the Netherlands, confirmed that low dose colchicine was safe, well-tolerated over the long-term, and significantly reduced the risk of cardiovascular death, heart attack, and ischemic stroke in patients with chronic coronary disease.
The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.
The American College of Cardiology's National Cardiovascular Data Registry was the source of data for research published throughout 2016, including a study examining if atrial fibrillation patients are being prescribed oral anticoagulants, how appropriate use criteria correlates to angioplasty rates and the variation among racial groups for revascularization procedures.
Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.
› Verified 2 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
An Australian-Dutch trial led by Perth GenesisCare cardiologists, Professor Peter Thompson and Dr Mark Nidorf, in collaboration with the Dutch Network for Cardiovascular Research (WCN) in the Netherlands, confirmed that low dose colchicine was safe, well-tolerated over the long-term, and significantly reduced the risk of cardiovascular death, heart attack, and ischemic stroke in patients with chronic coronary disease.
The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.
The American College of Cardiology's National Cardiovascular Data Registry was the source of data for research published throughout 2016, including a study examining if atrial fibrillation patients are being prescribed oral anticoagulants, how appropriate use criteria correlates to angioplasty rates and the variation among racial groups for revascularization procedures.
Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.
› Verified 2 days ago
| Entity Name | Cleveland Anesthesia Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154407955 PECOS PAC ID: 7113830050 Enrollment ID: O20031107000151 |
News Archive
An Australian-Dutch trial led by Perth GenesisCare cardiologists, Professor Peter Thompson and Dr Mark Nidorf, in collaboration with the Dutch Network for Cardiovascular Research (WCN) in the Netherlands, confirmed that low dose colchicine was safe, well-tolerated over the long-term, and significantly reduced the risk of cardiovascular death, heart attack, and ischemic stroke in patients with chronic coronary disease.
The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.
The American College of Cardiology's National Cardiovascular Data Registry was the source of data for research published throughout 2016, including a study examining if atrial fibrillation patients are being prescribed oral anticoagulants, how appropriate use criteria correlates to angioplasty rates and the variation among racial groups for revascularization procedures.
Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Deana Mamari, DEANA 9500 Euclid Ave, Cleveland, OH 44195-0001 Ph: () - | Deana Mamari, DEANA 18200 Lorain Ave, Cleveland, OH 44111-5605 Ph: (216) 316-2697 |
News Archive
An Australian-Dutch trial led by Perth GenesisCare cardiologists, Professor Peter Thompson and Dr Mark Nidorf, in collaboration with the Dutch Network for Cardiovascular Research (WCN) in the Netherlands, confirmed that low dose colchicine was safe, well-tolerated over the long-term, and significantly reduced the risk of cardiovascular death, heart attack, and ischemic stroke in patients with chronic coronary disease.
The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.
The American College of Cardiology's National Cardiovascular Data Registry was the source of data for research published throughout 2016, including a study examining if atrial fibrillation patients are being prescribed oral anticoagulants, how appropriate use criteria correlates to angioplasty rates and the variation among racial groups for revascularization procedures.
Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.
› Verified 2 days ago
Shannon Kelly, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Olivia Kehoe, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-1000 | |
Brian Michael Wheatley, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Nicole M Moses, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Michael Marcotte, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Thomas Bruno, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7330 | |
Gregory G Kychun, AA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7330 |